Disruption of these pathways or coactivators leads to selective suppression of cell growth and proliferation of PAX3-FOXO1-expressing ARMS cell lines, and thus represents attractive therapeutic strategies. Here, FOXO1 is linked to alveolar rhabdomyosarcoma.